RxDoctor Payments Data

William Cote

Family · Johnson City, TNNPI 1740383157

Payments from drug & device makers

$2,783in general payments, 2019–2025

Across 150 payments — averaging $18.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$466
  • Lilly USA, LLC$237
  • Novo Nordisk$225
  • Bayer$201
  • Pfizer$87
  • plus $373 from 13 others

What the payments were for

  • Food & beverage$2,772100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,783 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$45,303
Medicare patients
138
Services billed
1,612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$60,613
MounjaroTirzepatide40$43,476
JardianceEmpagliflozin36$33,281
OzempicSemaglutide20$21,532
FarxigaDapagliflozin Propanediol21$21,125
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$15,344
JanumetSitagliptin Phos/Metformin Hcl11$7,023
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$5,343
PremarinEstrogens, Conjugated13$4,225
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,727
Omeprazole196$3,524
Gabapentin166$2,555
Mometasone Furoate21$1,867
Tizanidine Hcl85$1,834
Atorvastatin Calcium201$1,781

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$87$64,83962 claims
Lilly USA, LLCMounjaro$237$43,47640 claims
Boehringer IngelheimJardiance$62$33,28136 claims
Novo NordiskOzempic$225$21,53220 claims
AstraZenecaFarxiga$1,195$21,12521 claims
GSKTrelegy Ellipta$66$15,34415 claims
MerckJanumet$18$7,02311 claims
AbbVieSynthroid$466$1,10512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.

Other family in Johnson City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →